This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
Uploading C:\STNEXP4\QUERIES\383c.str

L7 STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l7
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 17:09:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 87151 TO ITERATE

1.1% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 0

L8 0 SEA SSS SAM L7

L9 0 L8

=> s l7 full

REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 17:10:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 22.9% PROCESSED 400000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.06

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**



ethyl 2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylate



3-trans-dimethyl-amino-4-phenyl-4-trans-carbethoxy-cyclohexene



ethyl 3-dimethylamino-2-phenylpropionate

C:\STNEXP4\QUERIES\383.str





chain nodes :
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
ring/chain nodes :
7 8 9 16 17 18 19 20
chain bonds :
3-41 4-42 5-39 5-40 6-37 6-38 11-25 12-24 13-23 14-21 15-22 17-29 17-30 17-31
18-26 18-27 18-28 19-32 19-33 20-34 20-35 20-36
ring/chain bonds :
1-7 1-10 2-16 7-8 7-9 9-19 16-17 16-18 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
1-7 1-10 19-20
exact bonds :
1-2 1-6 2-3 2-16 3-4 3-41 4-5 4-42 5-6 5-39 5-40 6-37 6-38 7-8 7-9 9-19
11-25 12-24 13-23 14-21 15-22 16-17 16-18 17-29 17-30 17-31 18-26 18-27 18-28
19-32 19-33 20-34 20-35 20-36
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS
39:CLASS 40:CLASS 41:CLASS 42:CLASS

```
     (FILE 'HOME' ENTERED AT 16:58:35 ON 20 MAY 2004)

     FILE 'CAPLUS' ENTERED AT 16:58:40 ON 20 MAY 2004
L1              STRUCTURE UPLOADED
                S L1

     FILE 'REGISTRY' ENTERED AT 16:59:05 ON 20 MAY 2004
L2            1 S L1

     FILE 'CAPLUS' ENTERED AT 16:59:06 ON 20 MAY 2004
L3            2 S L2
                S L1

     FILE 'REGISTRY' ENTERED AT 16:59:20 ON 20 MAY 2004
L4           32 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 16:59:21 ON 20 MAY 2004
L5          220 S L4 FULL
L6            1 S L5 AND PROPIONIC ACID

     FILE 'STNGUIDE' ENTERED AT 17:04:33 ON 20 MAY 2004

     FILE 'CAPLUS' ENTERED AT 17:09:22 ON 20 MAY 2004
L7              STRUCTURE UPLOADED
                S L7

     FILE 'REGISTRY' ENTERED AT 17:09:57 ON 20 MAY 2004
L8            0 S L7

     FILE 'CAPLUS' ENTERED AT 17:09:58 ON 20 MAY 2004
L9            0 S L8
                S L7

     FILE 'REGISTRY' ENTERED AT 17:10:09 ON 20 MAY 2004
L10           0 S L7 FULL

     FILE 'CAPLUS' ENTERED AT 17:10:15 ON 20 MAY 2004
L11           0 S L10 FULL

=> s l5 and dimethyl
        320038 DIMETHYL
L12          2 L5 AND DIMETHYL

=> s l5 and dimethylamino
         66809 DIMETHYLAMINO
L13         37 L5 AND DIMETHYLAMINO

=> s l5 and dimethylamino and phenyl
         66809 DIMETHYLAMINO
        311574 PHENYL
L14         35 L5 AND DIMETHYLAMINO AND PHENYL

=> s l14 and propinic acid
             3 PROPINIC
       3819309 ACID
             2 PROPINIC ACID
                 (PROPINIC(W)ACID)
L15          0 L14 AND PROPINIC ACID

=> s l14 and propionic acid
         50822 PROPIONIC
       3819309 ACID
         44734 PROPIONIC ACID
                 (PROPIONIC(W)ACID)
L16          0 L14 AND PROPIONIC ACID

=> s l14 and ethylester
           274 ETHYLESTER
```

```
=>
Uploading C:\STNEXP4\QUERIES\383.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
   REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.




SAMPLE SEARCH INITIATED 16:59:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1566 TO ITERATE

 63.9% PROCESSED    1000 ITERATIONS                          1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        28947 TO    33693
PROJECTED ANSWERS:               1 TO      106

L2            1 SEA SSS SAM L1



L3           2 L2

=> s l1 full
   REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.




FULL SEARCH INITIATED 16:59:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  32455 TO ITERATE

100.0% PROCESSED   32455 ITERATIONS                        32 ANSWERS
SEARCH TIME: 00.00.01

L4           32 SEA SSS FUL L1



L5         220 L4

=> d l3 1-2 ibib abs hitstr
```

```
L17          0 L14 AND ETHYLESTER

=> s l14 and ethyl and ester
       411124 ETHYL
       544281 ESTER
L18          5 L14 AND ETHYL AND ESTER

=> d 1-5 ibib abs hitstr

L18  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:        2004:367260  CAPLUS
TITLE:                   Solid drug delivery systems for opiates, opioids and
                         stimulants that are protected against abuse using
                         antagonists
INVENTOR(S):             Bartholomaeus, Johannes; Langner, Klaus-Dieter
PATENT ASSIGNEE(S):      Gruenenthal GmbH, Germany
SOURCE:                  Ger. Offen., 15 pp.
                         CODEN: GWXXBX
DOCUMENT TYPE:           Patent
LANGUAGE:                German
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     DE 10250088        A1   20040506      DE 2002-10250088 20021025
     WO 2004037260      A1   20040506      WO 2003-EP11785  20031024
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
             GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                  DE 2002-10250088 A  20021025
AB   The invention concerns two-compartment solid drug delivery systems for
     opiates, opioids and stimulants in order to prevent drug abuse; one
     compartment includes the drug the other compartment contains an antagonist
     or antagonists to the drug.  When drugs are used for medical purpose, the
     antagonist is not dissolved.  In case the formulation is disintegrated,
     and/or extracted for drug overuse, the antagonists are in the same phase as
     the drug for action.  Layered tablets can be produced; or identical, but
     not labeled tablets, pellets are prepared from drug and antagonist.  Thus a
     two layer tablet contained (mg): in the coating: naltrexone hydrochloride
     50; Cutina HR 50; in the outer layer: morphine sulfate pentahydrate 60;
     methylhydroxy Pr cellulose 100; microcryst. cellulose 165; lactose
     monohydrate 165; magnesium stearate 5; silica 5.
IT   INDEXING IN PROGRESS
IT   20380-56-7, 3-Cyclohexene-1-carboxylic acid, 2-(
     dimethylamino)-1-phenyl-, ethyl ester
     , (1R,2R)-rel- 51931-66-9, 3-Cyclohexene-1-carboxylic acid, 2-(
     dimethylamino)-1-phenyl-, ethyl ester
     , (1R,2S)-rel-
     RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (solid drug delivery systems for opiates, opioids and stimulants that
        are protected against abuse using antagonists)
RN   20380-56-7  CAPLUS
CN   3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester,
     (1R,2R)-rel- (9CI)  (CA INDEX NAME)

Relative stereochemistry.
```



RN 51931-66-9 CAPLUS
CN 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:5117 CAPLUS
DOCUMENT NUMBER: 140:47586
TITLE: Solid, delayed-release pharmaceutical composition comprising tilidine hydrochloride
INVENTOR(S): Schumann, Christof; Renz, Jessica
PATENT ASSIGNEE(S): Stada Arzneimittel A.-G., Germany
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1374859	A1	20040102	EP 2003-14715	20030627

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: DE 2002-10229216 A 20020628

AB The invention concerns a solid, stable formulation of tilidine hydrochloride hemihydrate that contains retarding agents, excipients, but no agents that would form complexes with two-and three-valent metals and pyrazole acetic acid. Addnl. the morphine antagonist naloxone can be included into the formulations. Thus a tablet contained (mg/tablet): tilidine hydrochloride x 0.5 102.9; naloxone hydrochloride dihydrate 8.8; hydroxypropylmethyl cellulose (4000 cP) 55; hydroxypropyl methylcellulose (100 cP) 35; microcryst. cellulose 149 mg; silica 3; magnesium stearate 2. The tablets were coated with Opadry.

IT **27107-79-5**, Tilidine hydrochloride
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid, delayed-release pharmaceutical composition comprising tilidine hydrochloride)

RN 27107-79-5 CAPLUS
CN 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, hydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT **255733-17-6**, 3-Cyclohexene-1-carboxylic acid, 2-(**dimethylamino**)-1-**phenyl**-, **ethyl ester**, hydrochloride, hydrate (2:1), (1R,2S)-rel-
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(solid, delayed-release pharmaceutical composition comprising tilidine hydrochloride)
RN 255733-17-6 CAPLUS
CN 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, hydrochloride, hydrate (2:1), (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

● 1/2 H_2O

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:1006739 CAPLUS
DOCUMENT NUMBER: 140:47524
TITLE: Drug delivery systems with abuse-protection for tranquilizers, hypnotics, sedatives and stimulants containing thickening agents
INVENTOR(S): Bartholomaeus, Johannes; Kugelmann, Heinrich
PATENT ASSIGNEE(S): Gruenenthal G.m.b.H., Germany
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105808	A1	20031224	WO 2003-EP6314	20030616

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10250083 A1 20031224 DE 2002-10250083 20021025
PRIORITY APPLN. INFO.: DE 2002-10227077 A 20020617
DE 2002-10250083 A 20021025

AB The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. Said agent forms, when a necessary min. amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid Thus a matrix tablet contained (mg): (-)-(1R,2R)-3-(3-**dimethylamino**-1-**ethyl**-2-methyl-propyl)phenol hydrochloride 100; hydroxypropyl methylcellulose 70; Xanthan 10; cellulose 123; silica 4; magnesium stearate 3.

IT **20380-56-7**, 3-Cyclohexene-1-carboxylic acid, 2-(**dimethylamino**)-1-**phenyl**-, **ethyl ester**
, (1R,2R)-rel- **51931-66-9**, 3-Cyclohexene-1-carboxylic acid, 2-(**dimethylamino**)-1-**phenyl**-, **ethyl ester**
, (1R,2S)-rel-
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug delivery systems with abuse-protection for tranquilizers, hypnotics, sedatives and stimulants containing thickening agents)

RN 20380-56-7 CAPLUS
CN 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 51931-66-9 CAPLUS
CN 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:513662 CAPLUS
DOCUMENT NUMBER: 133:89330
TITLE: Reduction of **ethyl** 3-**dimethylamino**-2-phenylpropionate content in solutions of **ethyl** 2-**dimethylamino**-1-**phenyl**-3-cyclohexene-1-carboxylate using

carboxylic acids.
INVENTOR(S): Thyes, Marco; Falkenberg, Wolfgang; Schneider, Ulrich
PATENT ASSIGNEE(S): Knoll Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000043353	A1	20000727	WO 2000-EP306	20000115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19902590	A1	20000727	DE 1999-19902590	19990122
TW 462958	B	20011111	TW 1999-88122113	19991216
CA 2359080	AA	20000727	CA 2000-2359080	20000115
BR 2000007646	A	20011016	BR 2000-7646	20000115
EP 1144361	A1	20011017	EP 2000-902598	20000115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002535303	T2	20021022	JP 2000-594771	20000115
RU 2201918	C1	20030410	RU 2001-123589	20000115
AU 766196	B2	20031009	AU 2000-24376	20000115
ZA 2001005537	A	20020705	ZA 2001-5537	20010705
NO 2001003528	A	20010717	NO 2001-3528	20010717

PRIORITY APPLN. INFO.: DE 1999-19902590 A 19990122
WO 2000-EP306 W 20000115

AB The amount of Et 3-**dimethylamino**-2-phenylpropionate (I) impurity in a solution of Et 2-**dimethylamino**-1-**phenyl**-3-cyclohexene-1-carboxylate (II) in a non-H2O miscible solvent is reduced by treatment with 0.5-2.0 equiv of carboxylic acid per mol II followed by stirring at 50-100°. Thus, II containing 1% I in cyclohexane was refluxed 2 h with HOAc; the mixture was treated with H2O and aqueous NaOH followed by phase separation to give II containing 0.05% I.

IT **17243-69-5P**
RL: PUR (Purification or recovery); PREP (Preparation)
(reduction of Et 3-**dimethylamino**-2-phenylpropionate content in solns. of Et 2-**dimethylamino**-1-**phenyl**-3-cyclohexene-1-carboxylate using carboxylic acids)

RN 17243-69-5 CAPLUS
CN 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1977:593563 CAPLUS
DOCUMENT NUMBER: 87:193563
TITLE: Metabolism of trans-D,L-2-(**dimethylamino**)-1-

phenyl-3-cyclohexene-1-carboxylic acid
ethyl ester hydrochloride
(tilidine-HCl). Part 3. Renal metabolite elimination in rats, dog, and man

AUTHOR(S): Vollmer, K. O.; Von Hodenberg, A.
CORPORATE SOURCE: Forschungsinst., Goedecke A.-G., Freiburg/Br., Fed. Rep. Ger.

SOURCE: Arzneimittel-Forschung (1977), 27(9), 1706-13
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: German

GI



I

AB Renal elimination of tilidine-HCl (I) [**27107-79-5**] was similar in the rat, dog, and man. After oral administration of I-14C 50-60, 80, and >90% of the applied dose was eliminated in the urine in the resp. species. The half/life of renal 14C elimination was 8 h in the rat and man, and the elimination was faster in the dog. In all species, about 17% of the urinary radioactivity was in nonpolar metabolites. About 2-3% each was in nortilidine [38677-94-0] and bisnortilidine [53948-51-9], and <0.2% in unchanged I. Most of the polar metabolites were glucuronides. Five new metabolites, oxygenated derivs. of nortilidine and bisnortilidine, were isolated from rat urine.

IT **27107-79-5**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of)

RN 27107-79-5 CAPLUS

CN 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, hydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

=>